bluuebunny/crossref_metadata_2025 huggingface dataset:
Effect of C/N Ratio Levels and Stocking Density of Catla Spawn (Gibelion catla) on Water Quality, Growth Performance, and Biofloc Nutritional Composition in an Indoor Biofloc System
Authors: Solanki Sonia , Meshram S. J. , Dhamagaye H. B. , Naik S. D. , Shingare P. E. , Yadav B. M.
Published: June 2023

A 20-day 3 ∗ 3 factorial experiment was conducted in 100 L HDPE experimental tanks to investigate the effect of the C/N ratio (10, 15, and 20) and stocking density (3, 4, and 5 spawn L−1) on Gibelion catla spawn nursery rearing in the indoor biofloc system. Rice bran was used as the carbon source for manipulating C/N ratios. Each treatment was stocked with catla spawn of average length (6.7 ± 0.4 mm) and average weight (1.6 ± 0.2 mg). Water parameters showed that increasing the C/N ratio from 10 to 20 significantly (

p
<
0.05

) reduced total ammonia nitrogen (TAN) and nitrite nitrogen (NO2-N) and increased nitrate nitrogen (NO3-N) in the water. The insignificant difference (

p
>
0.05

) and lowest final average length, average length gain, average weight gain, and specific growth rate (SGR) were recorded in C/N ratios of 10 and 15 compared to a C/N ratio of 20. A significant difference (

p
<
0.05

) in survival was observed with the increasing C/N ratio. Increasing the fish stocking density resulted in higher mortality. However, a higher amount of fry produced was observed in the treatments with 3 and 4 spawn L−1. Crude protein content increased significantly (

p
<
0.05

) with the increasing C/N ratio with higher content in C/N 20. No significant difference (

p
>
0.05

) in proximate composition of biofloc was observed in different stocking density groups. In conclusion, the application of the biofloc technology with a C/N ratio of 20 at a stocking density of 4 spawn L−1 could be recommended to increase the production of catla fry in the indoor biofloc system.
The Impact of COVID-19 Outbreak on CO2 Emissions in the Ten Countries with the Highest Carbon Dioxide Emissions
Authors: Ronaghi Marzieh , Scorsone Eric
Published: June 2023

The environmental pollution during the COVID-19 crisis has declined dramatically due to quarantines that have severely reduced transport and industry but has had little effect on the steady rise in CO2 concentrations in the atmosphere. Through the Paris Agreement, countries are working to reduce the emissions of these pollutants, for example, by burning fossil fuels. These greenhouse gases trap heat near the earth’s surface and raise the temperature. This global warming threatens global food resources. In times of corona crisis and environmental pollution, especially in countries with the highest CO2 emissions, governance is a key factor that explains the poor economic, social, and environmental performance of many countries. Governance plays an important role in controlling these crises. In this study, the World Bank’s governance indicators have been used to examine the relationship between governance and economic performance and its impact on CO2 emissions during the COVID-19 outbreak period. Also, the Tobit panel model with a limited-dependent model from 2011 to 2020 has been used. Several economic factors and governance variables are also considered. Given the negative relationship between governance and CO2 emissions during the COVID-19 outbreak, the role of governance in reducing environmental pollution is emphasized, and it is shown that policymakers can take appropriate measures by implementing good governance and enforcing the right laws to control the corona epidemic and also reduce carbon emissions in the long run.
Vibration Analysis of Low Height-to-Span Ratio Pedestrian Bridge under Human-Induced Excitation
Authors: Wang Wei , An Rui , Huang Huihui , Li Jie , Niu Jinghang , Liao Huan , Jiao Jian , Li Zhiqiang , Tao Yuekai
Published: June 2023

Driven by the aesthetic pursuit of the urban landscape, pedestrian bridges become longer, lighter, and slender, which may be susceptible to unacceptable vibrations induced by human activities. This paper presented on-site vibration tests of a pedestrian bridge with a very low height-to-span ratio (1/60). The vibration characteristics and dynamic responses were analyzed using environmental, heel-drop, and walking tests. Then, a verified finite model was established to investigate the effect of the height-to-span ratio and the concrete filling ranges of tree-like steel piers on the vibration characteristics and acceleration responses of this kind of pedestrian bridges. Moreover, the relationship between different peak accelerations under heel-drop and walking at various frequencies by the same person was detailed and studied experimentally and by computer simulation, after which the ratios of the peak acceleration during walking and the one under heel-drop were recommended. Finally, a method that demonstrates the feasibility of predicting the peak acceleration of pedestrian bridges of a small height-to-span ratio across a range of walking frequencies was proposed based on a simplified heel-drop load model developed according to 60 time-history records.
Emergence of New Segments of Swiss Wine Consumers: A Comparison with a Segmentation Study from 2011
Authors: Brunner Thomas A. , Schnetzer Thomas , Delley Mathilde
Published: June 2023

This study aimed to examine the various Swiss wine consumer segments, evaluate whether and how these segments had changed during the past decade, and formulate recommendations for targeted marketing. Data were collected through an online survey involving randomly selected Swiss households who were invited using flyers; the final sample size was N = 512. With the use of a shortened version of the questionnaire devised for a similar study published in 2011, we were able to compare the results of the said study with the present results. The results of the principal component analyses revealed eight factors. The factor scores were then used in hierarchical cluster analyses, which in turn revealed seven distinct segments of wine consumers. Four of these had already been identified 10 years ago: involved (21.9%), price-conscious (20.3%), lowbrow (16.0%), and image-oriented (5.3%) consumers. Three new segments emerged: local (15.2%), traditional (11.9%), and relaxation-seeking (9.4%) consumers. Our results show that each wine seller has its own place in the market and can benefit from the present study, which determines the appropriate marketing mix for a specific segment.
Optical Coherence Tomography Angiography Characteristics of Polypoidal Lesions in Caucasians
Authors: Ahmed-Balestra Daniel , Graf Alexandra , Stattin Martin , Haas Anna-Maria , Kickinger Stefan , Jacob Michael , Zehetner Claus , Krepler Katharina , Ansari-Shahrezaei Siamak
Published: June 2023

Purpose. The aim of the study is to analyze the swept source‐optical coherence tomography angiography (SS‐OCTA) characteristics of polypoidal lesions in Caucasian patients. Methods. In this retrospective observational case series, 43 polypoidal lesions in 32 eyes of 32 patients were diagnosed using indocyanine green angiography (ICGA) and compared to SS‐OCTA at a tertiary medical retina center (Clinic Landstraße, Vienna Healthcare Group, Austria) between June 2017 and March 2020. Vascularity was identified by color‐coded B‐scan SS‐OCTA while morphology was described as revealed by en face SS‐OCTA after alignment with ICGA‐confirmed findings. Results. In total, SS‐OCTA detected all polypoidal lesions, as identified by ICGA. On B‐scan SS‐OCTA, circumscribed flow was detected in 33 (76.7%) polypoidal lesions and diffuse flow in 10 (23.3%) lesions. On en face SS‐OCTA, polypoidal lesions appeared morphologically as 19 tangled vessel balls (44.2%), 6 tangled vessel balls next to dilated vessels (13.9%), 8 vascular dilatations (18.6%), and 8 ill‐defined vascular networks (18.6%), leaving 2 lesions (4.6%) undetected. Circumscribed flow was significantly associated with tangled vessel balls (p = 0.005). Conclusion. This study highlights the importance of a multimodal imaging approach, including SS‐OCTA, for the evaluation of polypoidal lesions. Our findings suggest a morphological heterogeneity of vascular patterns in Caucasian patients with polypoidal lesions, as pictured by SS‐OCTA.
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Authors: Exposito Francisco , Redrado Miriam , Houry Maeva , Hastings Katherine , Molero-Abraham Magdalena , Lozano Teresa , Solorzano Jose Luis , Sanz-Ortega Julian , Adradas Vera , Amat Ramon , Redin Esther , Leon Sergio , Legarra Naroa , Garcia Javier , Serrano Diego , Valencia Karmele , Robles-Oteiza Camila , Foggetti Giorgia , Otegui Nerea , Felip Enriqueta , Lasarte Juan J. , Paz-Ares Luis , Zugazagoitia Jon , Politi Katerina , Montuenga Luis , Calvo Alfonso
Published: June 2023

Immunotherapy resistance in non–small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can be shaped by the mutational landscape of the tumor. Here, we observed genetic alterations in the PTEN/PI3K/AKT/mTOR pathway and/or loss of PTEN expression in >25% of patients with NSCLC, with higher frequency in lung squamous carcinomas (LUSC). Patients with PTEN-low tumors had higher levels of PD-L1 and PD-L2 and showed worse progression-free survival when treated with immunotherapy. Development of a Pten-null LUSC mouse model revealed that tumors with PTEN loss were refractory to antiprogrammed cell death protein 1 (anti–PD-1), highly metastatic and fibrotic, and secreted TGFβ/CXCL10 to promote conversion of CD4+ lymphocytes into regulatory T cells (Treg). Human and mouse PTEN-low tumors were enriched in Tregs and expressed higher levels of immunosuppressive genes. Importantly, treatment of mice bearing Pten-null tumors with TLR agonists and anti-TGFβ antibody aimed to alter this immunosuppressive microenvironment and led to tumor rejection and immunologic memory in 100% of mice. These results demonstrate that lack of PTEN causes immunotherapy resistance in LUSCs by establishing an immunosuppressive tumor microenvironment that can be reversed therapeutically.

Significance:

PTEN loss leads to the development of an immunosuppressive microenvironment in lung cancer that confers resistance to anti–PD-1 therapy, which can be overcome by targeting PTEN loss–mediated immunosuppression.
Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma
Authors: Chen Chen , Shin June Ho , Fang Zhuoqing , Brennan Kevin , Horowitz Nina B. , Pfaff Kathleen L. , Welsh Emma L. , Rodig Scott J. , Gevaert Olivier , Gozani Or , Uppaluri Ravindra , Sunwoo John B.
Published: June 2023

In head and neck squamous cell carcinoma (HNSCC), a significant proportion of tumors have inactivating mutations in the histone methyltransferase NSD1. In these tumors, NSD1 inactivation is a driver of T-cell exclusion from the tumor microenvironment (TME). A better understanding of the NSD1-mediated mechanism regulating infiltration of T cells into the TME could help identify approaches to overcome immunosuppression. Here, we demonstrated that NSD1 inactivation results in lower levels of H3K36 dimethylation and higher levels of H3K27 trimethylation, the latter being a known repressive histone mark enriched on the promoters of key T-cell chemokines CXCL9 and CXCL10. HNSCC with NSD1 mutations had lower levels of these chemokines and lacked responses to PD-1 immune checkpoint blockade. Inhibition of KDM2A, the primary lysine demethylase that is selective for H3K36, reversed the altered histone marks induced by NSD1 loss and restored T-cell infiltration into the TME. Importantly, KDM2A suppression decreased growth of NSD1-deficient tumors in immunocompetent, but not in immunodeficient, mice. Together, these data indicate that KDM2A is an immunotherapeutic target for overcoming immune exclusion in HNSCC.

Significance:

The altered epigenetic landscape of NSD1-deficient tumors confers sensitivity to inhibition of the histone-modifying enzyme KDM2A as an immunotherapeutic strategy to stimulate T-cell infiltration and suppress tumor growth.
Sex-specific Associations between Body Mass Index and Thyroid Cancer Incidence among Korean Adults
Authors: Kim Kyoung-Nam , Kim Kyungsik , Lee Sangjun , Park Sue K.
Published: June 2023

Background:

The potential differences by sex in the association between body mass index (BMI) and thyroid cancer risk remain unconfirmed.

Methods:

Data from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS; 2002–2015; population size = 510,619) and the Korean Multi-center Cancer Cohort (KMCC) data (1993–2015; population size = 19,026) were used. We constructed Cox regression models, adjusted for potential confounders, to evaluate the association between BMI and thyroid cancer incidence in each cohort, and assessed the consistency of the results.

Results:

In the NHIS-HEALS, 1,351 and 4,609 incident thyroid cancer cases occurred during the follow-up among men and women, respectively. Compared with BMI of 18.5–22.9 kg/m2, BMI of 23.0–24.9 [no. of cases = 410; HR, 1.25; 95% confidence interval (CI), 1.08–1.44], 25.0–29.9 (no. of cases = 522; HR, 1.32; 95% CI, 1.15–1.51), and ≥30.0 kg/m2 (no. of cases = 48; HR, 1.93; 95% CI, 1.42–2.61) were associated with an increased risk of incident thyroid cancer among males. Among females, BMI of 23.0–24.9 (no. of cases = 1,300; HR, 1.17; 95% CI, 1.09–1.26) and 25.0–29.9 (no. of cases = 1,406; HR, 1.20; 95% CI, 1.11–1.29) were associated with incident thyroid cancer. The analyses using the KMCC demonstrated results consistent with wider CIs.

Conclusions:

Sex differences in the associations between BMI and thyroid cancer incidence were observed in Korean cohorts.

Impact:

BMI <23 kg/m2 may help prevent incident thyroid cancer, especially among men.
Supplementary Table S5: STING-based Clinical Trials from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: June 2023

STING-based Clinical Trials
Table S3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O'Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: June 2023

Summary of anti-tumor activity endpoints in patients treated with eganelisib combination therapy by tumor type
Figure S6 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: June 2023

Figure S6
Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O'Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: June 2023

Geometric mean (geometric CV%) of eganelisib PK parameters in patients with solid tumors in the monotherapy cohort
Supplementary Methods S1 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

Supplementary Methods
Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew Stephen , Hieken Tina , McWilliams Robert R.
Published: June 2023

Outcomes by Subgroups of Primary Site, Adjuvant Radiation, and R0/R1 Resection Margin Status
Supplementary Table S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jérôme , Varga Matthew Gordon , Schweitzer Brock L. , Cremolini Chiara
Published: June 2023

Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
Fig S6 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

(A) Comparison between ctDNA molecular responses and clinical benefit determined through radiographic imaging for patients treated with immunotherapy-containing regimens revealed concordance between each assessment (p = 0.019, Fisher’s exact test). For these comparisons, durable clinical benefit (DCB) was defined as a lack of progression or death within 6 months of treatment initiation; non-durable benefit (NDB) was defined as progression or death within 6 months of treatment initiation. Comparison between ctDNA molecular responses and radiographic assessments (PR/CR vs SD/PD/MR) for the determination of (B) overall survival (OS) at 64 months (maximum OS observed in patients with date of death recorded) and progression-free survival (PFS) at (C) 6 months, (D) 9 months and (E) 14 months (maximum PFS observed in patients with clinically documented progression following systemic treatment), is shown for all 33 patients included in the study cohort.
Fig S4 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

(A) Genome-wide log2 copy ratios derived from targeted error-correction sequencing (TEC-Seq) data using CNVkit (Methods) are shown for each plasma sample, with copy number gains indicated in red and losses indicated in blue. Each row corresponds to a single plasma sample and rows are ordered with respect to consecutive sampling timepoints analyzed for each patient. (B-F) Genome-wide copy number profiles are shown for patients with matched tumor (WES) and plasma samples analyzed. We observed a high concordance between copy number profiles derived by whole exome sequencing, our approach (CNVkit) and ichorCNA for patients with detectable aneuploidy in plasma. (B) Patient 3 had undetectable ctDNA according to tumor-specific sequence alterations. However, this patient was classified as a molecular responder based on decrease of plasma aneuploidy to normal ploidy by the week 8 timepoint. (C) Patient 5 was classified as a molecular progressor based on the presence of tumor-specific sequence alterations and plasma aneuploidy across all timepoints analyzed. (D) Similarly, patient 9 was classified as a molecular progressor based on the persistence of mutations and plasma aneuploidy, which were detectable across all sampled timepoints from this patient. (E, F) Plasma copy number profiles for patients 11 and 14 indicated ploidy close to normal ploidy across all timepoints analyzed. These patients were classified as molecular responders based on tumor-derived sequence alterations.
Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Authors: Lozano-Rabella Maria , Garcia-Garijo Andrea , Palomero Jara , Yuste-Estevanez Anna , Erhard Florian , Farriol-Duran Roc , Martín-Liberal Juan , Ochoa-de-Olza Maria , Matos Ignacio , Gartner Jared J. , Ghosh Michael , Canals Francesc , Vidal August , Piulats Josep Maria , Matías-Guiu Xavier , Brana Irene , Muñoz-Couselo Eva , Garralda Elena , Schlosser Andreas , Gros Alena
Published: June 2023

Includes the list of peptides derived from NSM identified at 0.02 FDR and ALC>=30
Table S8 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Genes enriched in NEAT1-high macrophages
Table S5 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

LncRNA transcriptome analysis in glioblastoma (GSE121810)
Table S3 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

LncRNA transcriptome analysis in melanoma (GSE78220)
Tables S1 and S2 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

S1: Baseline patient characteristics in TMA 376 vs TMA 469S2: Patients treated with Ipi/Nio vs anti-PD-1 alone
Figure S8 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

Supplementary Figure 8: Members of the interferon signaling pathway and ICI treatment regimen predict survival in Gide et al
Figure S3 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

Supplemental Figure 3: STAT1 in the tumor compartment consistently predicts ICI response and survival but not stromal STAT1 or tumor/stromal pSTAT1Y701
Data from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

AbstractPurpose:
IFN signaling in the tumor microenvironment is a critical determinant of both response and resistance of cancer to immune checkpoint inhibitors (ICI). We hypothesized that distinct patterns of IFN signaling in melanoma are associated with clinical response or resistance to ICIs.
Experimental Design:
Two tissue microarrays containing samples from 97 patients with metastatic melanoma who received nivolumab, pembrolizumab, or a combination of ipilimumab and nivolumab at Yale New Haven Hospital between 2011 and 2017 were randomized into discovery and validation cohorts. Samples were stained and visualized using multiplexed immunofluorescence microscopy for STAT1, STAT1 phosphorylated at Y701 (pSTAT1Y701), and PD-L1, and signals were quantified using the automated quantitative analysis method of quantitative immunofluorescence. Treatment response was assessed using RECIST, and overall survival was analyzed. For in vitro studies, human melanoma cell lines were stimulated with IFNγ and IFNβ, and Western blotting was performed.
Results:
Pretreatment STAT1 levels were higher in responders to ICIs [complete response/partial response/stable disease (SD) for > 6 months] than in nonresponders (SD < 6 months/progressive disease). Higher pretreatment STAT1 levels were associated with improved survival after ICIs in both the discovery and validation cohorts. Western blot analysis of human melanoma cell lines stimulated with IFN demonstrated distinct patterns of upregulation of STAT1 compared with pSTAT1Y701 and PD-L1. When combining STAT1 and PD-L1 markers, patients with STAT1highPD-L1low tumors had improved survival compared with those with STAT1lowPD-L1high tumors.
Conclusions:
STAT1 may better predict melanoma response to ICIs than current strategies, and combined STAT1 and PD-L1 biomarkers may provide insight into IFN-responsive versus IFN-resistant states.
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer
Authors: Ghosh Susmita , Fan Fan , Powell Reid T. , Roszik Jason , Park Yong Sung , Stephan Clifford , Sebastian Manu , Tan Lin , Sorokin Alexey V. , Lorenzi Philip L. , Kopetz Scott , Ellis Lee M. , Bhattacharya Rajat
Published: June 2023

Mutations in KRAS are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most KRAS mutations is difficult; even the recently developed KRASG12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting mitogen-activated protein kinase kinase (MEK), a downstream mediator of RAS, have also been ineffective in colorectal cancer. To identify drugs that can enhance the efficacy of MEK inhibitors, we performed unbiased high-throughput screening using colorectal cancer spheroids. We used trametinib as the anchor drug and examined combinations of trametinib with the NCI-approved Oncology Library version 5. The initial screen, and following focused validation screens, identified vincristine as being strongly synergistic with trametinib. In vitro, the combination strongly inhibited cell growth, reduced clonogenic survival, and enhanced apoptosis compared with monotherapies in multiple KRAS-mutant colorectal cancer cell lines. Furthermore, this combination significantly inhibited tumor growth, reduced cell proliferation, and increased apoptosis in multiple KRAS-mutant patient-derived xenograft mouse models. In vivo studies using drug doses that reflect clinically achievable doses demonstrated that the combination was well tolerated by mice. We further determined that the mechanism underlying the synergistic effect of the combination was due to enhanced intracellular accumulation of vincristine associated with MEK inhibition. The combination also significantly decreased p-mTOR levels in vitro, indicating that it inhibits both RAS-RAF-MEK and PI3K-AKT-mTOR survival pathways. Our data thus provide strong evidence that the combination of trametinib and vincristine represents a novel therapeutic option to be studied in clinical trials for patients with KRAS-mutant mCRC.

Significance:

Our unbiased preclinical studies have identified vincristine as an effective combination partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in patients with KRAS-mutant colorectal cancer.
Targeting c-Jun Is a Potential Therapy for Luminal Breast Cancer Bone Metastasis
Authors: Han Yuxuan , Katayama Shota , Futakuchi Mitsuru , Nakamichi Kazuya , Wakabayashi Yutaro , Sakamoto Mai , Nakayama Jun , Semba Kentaro
Published: June 2023

Luminal breast cancer has the highest bone metastasis frequency among all breast cancer subtypes; however, its metastatic mechanism has not been elucidated because of a lack of appropriate models. We have previously developed useful bone metastatic cell lines of luminal breast cancer using MCF7 cells. In this study, we characterized bone metastatic MCF7-BM cell lines and identified c-Jun as a novel bone metastasis marker of luminal breast cancer. The protein level of c-Jun was upregulated in MCF7-BM cells compared with that in parental cells, and its deficiency resulted in the suppression of tumor cell migration, transformation, and reduced osteolytic ability. In vivo, dominant-negative c-Jun exhibited smaller bone metastatic lesions and a lower metastatic frequency. Histologic analysis revealed that c-Jun expression was heterogeneous in bone metastatic lesions, whereas c-Jun overexpression mediated a vicious cycle between MCF7-BM cells and osteoclasts by enhancing calcium-induced migration and releasing the osteoclast activator BMP5. Pharmacological inhibition of c-Jun by the Jun amino-terminal kinase (JNK) inhibitor JNK-IN-8 effectively suppressed tumorigenesis and bone metastasis in MCF7-BM cells. Furthermore, c-Jun downstream signals were specifically correlated with the clinical prognosis of patients with the luminal subtype of breast cancer. Our results illustrate the potential benefits of a therapy that targets c-Jun to prevent bone metastasis in luminal breast cancer.

Implications:

c-Jun expression mediates bone metastasis in luminal breast cancer by forming a vicious cycle in the bone microenvironment, which reveals potential strategies for subtype-specific bone metastasis therapy.
Figure 2 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Authors: Hamieh Mohamad , Mansilla-Soto Jorge , Rivière Isabelle , Sadelain Michel
Published: June 2023

"OR" logic-gate CAR T cell designs. A, Dual-CAR, two distinct fully functional CARs targeting different antigens are coexpressed on the surface of the same T cell. Identical or different costimulatory domains can be used. B, Tan-CARs, left, bivalent single CAR chain with two binding domains (scFvs) in tandem targeting two distinct antigens. Middle, bivalent single CAR chain with two distinct binding domains (VHH, single-domain antibodies) in tandem targeting different epitopes of the same antigen. Right, multivalent single CAR chain using designed ankyrin repeat proteins (DARPIn) in tandem targeting more than two antigens. C, Parallel-CAR, one fully functional CAR (second generation) and a chimeric costimulatory receptor (CCR) with identical hinge domains that allow CAR-CCR heterodimerization are coexpressed on the surface of the same T cell. D, Zip-CAR, Zip-CAR expressed on the surface of T cells binds to distinct Zip-Fv (Zip-scFv) targeting different antigens. Zip-CAR uses a leucine zipper adapter expressed on the T cells that bind to administered Zip-Fv specific for antigens A or B. E, CAR-BiTEs, CAR T cell coexpressing bispecific T cell engagers (BiTEs). BiTEs are directed against CD3 and an antigen distinct from the CAR target.
Data from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Authors: Sivakumar Smruthy , Moore Jay A. , Montesion Meagan , Sharaf Radwa , Lin Douglas I. , Colón Caterina I. , Fleishmann Zoe , Ebot Ericka M. , Newberg Justin Y. , Mills Jennifer M. , Hegde Priti S. , Pan Quintin , Dowlati Afshin , Frampton Garrett M. , Sage Julien , Lovly Christine M.
Published: June 2023

Abstract
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “real-world” SCLC cases. This large cohort allowed us to identify new recurrent alterations and genetic subtypes, including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), as well as rare cases that were human papillomavirus–positive. In our cohort, gene amplifications on 4q12 are associated with increased overall survival, whereas CCNE1 amplification is associated with decreased overall survival. We also identify more frequent alterations in the PTEN pathway in brain metastases. Finally, profiling cases of SCLC containing oncogenic drivers typically associated with NSCLC demonstrates that SCLC transformation may occur across multiple distinct molecular cohorts of NSCLC. These novel and unsuspected genetic features of SCLC may help personalize treatment approaches for this fatal form of cancer.
Significance:
Minimal changes in therapy and survival outcomes have occurred in SCLC for the past four decades. The identification of new genetic subtypes and novel recurrent mutations as well as an improved understanding of the mechanisms of transformation to SCLC from NSCLC may guide the development of personalized therapies for subsets of patients with SCLC.
Table S3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Antibodies for IHC
Table S1 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Patient characteristics
Fig. S9 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

CD33 IHC of LUAD and LUSQ tissues of a representative case from immune subtypes. (a) LUAD. (b)LUSQ. The number is the ratio of CD33 positive staining area per tissue area (percentage).
Fig. S8 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

IHC of LUAD and LUSQ tissues of a representative case from immune subtypes. The antibodies against CD20 and FOXP3 are used in LUAD (a) and LUSQ tissues (b).
Fig. S2 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Representative polychromatic dot plots demonstrating the gating strategy employed to identify the immune cell profile of TILs in NSCLC. Starting at the top left, the initial gate was to obtain live cells; next, leukocytes (CD45+) and epithelial cells (CD326+) were gated; finally, CD3+ cells and CD3- cells were separated. For CD3+ cells, a size gate was applied to identify NKT cells (CD3+ CD56+), CD3+CD4+ and CD3+CD8+ T cells. T cell subsets are displayed, including naïve (CD45RA+CD197+), central memory (CM: CD45RA-CD197+), effector memory (EM: CD45RA-CD197-), and effector memory cells re-expressing CD45RA (EMRA: CD45RA+CD197-). FOXP3-expressing CD4+ T cells were gated on CD4+ T cells: naïve Treg (Fr. I: CD45RA+FOXP3lo), effector Treg (Fr. II: CD45RA-FOXP3hi), and non-Treg (Fr. III: CD45RA-FOXP3lo). For CD3- cells, a size gate was applied to identify B (CD3-CD19+) and NK cells (CD3-CD56+). The myeloid cell lineage was also gated on CD3- cells: conventional DC (HLA-DR+CD11c+), plasmacytoid DC (HLA-DR+CD11c-CD123+), macrophage (CD68+SSChi) and monocytic MDSC (HLA-DRlo CD14+CD11b+CD33+). Ki-67-expressing cells were gated in CD8+NKT, CD4+NKT, CD4+T (NT, CM, EM, EMRA), CD8+T (NT, CM, EM, EMRA), Treg, B, NK, and mMDSC. PD-1-expressing cells were gated in CD4+T (naive, CM, EM, EMRA), CD8+T (naive, CM, EM, EMRA) and Treg cells. PD-L1-expressing cells were gated in CD8+T (NT, CM, EM, EMRA), and mMDSC. CTLA-4-expressing cells were gated in Treg cells.
FIGURE 2 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Immune subtypes based on TIL profiling using FCM; NAT (n = 157), LUAD [85; Cold (n = 19), Myeloid (n = 36), CD8 (n = 30)], LUSQ [50; Cold (n = 14), Myeloid (n = 19), CD8 (n = 17)]. A, Heat map of cell densities and �45 of immune cells in NSCLC tumors and NATs. Each column represents a patient; data were normalized by Z-scores to indicate relative compositions of immune cells. Cell density is presented as the log of each cell type. �45 is presented as each immune cell type/CD45. Heat maps of cell density and �45 of TILs in LUAD (B) and LUSQ (C) tissues. D, Cell densities and �45 of immune cell types in LUAD and LUSQ immune subtypes. Top, Cell density indicates immune cells. Bottom, �45 indicates immune cells. AD.Cold, AD.Myeloid, and AD.CD8 are LUAD subtypes Cold, Myeloid, and CD8, respectively. SQ.Cold, SQ.Myeloid, and SQ.CD8 are LUSQ subtypes Cold, Myeloid, and CD8, respectively. E, IHC staining for CD8 in a representative case from immune subtypes. For CD8, FOXP3, CD20, and Ki67, the positivity of each marker was given as the number of total positive cell number within each tissue core. For CD33, the ratio of CD33-positive staining area per tissue area was calculated. F, Immune cell counts by IHC staining in lung cancer tissues. G, CD8+ T cell–attractant chemokine gene expression in immune subtypes.
Atafona: registro de um mundo em ruínas
Authors: Valpassos Carlos Abraão Moura , Cunha Juliana Blasi
Published: June 2023

Atafona é uma praia situada no norte do estado do Rio de Janeiro, Brasil. É ali que deságua o rio Paraíba do Sul, depois de percorrer centenas de quilômetros e cruzar três estados federativos. Ao longo do século XX, Atafona constituiu-se como balneário de uma elite regional, que ali ergueu suas casas de veraneio e viveu o lugar, por mais de quatro gerações, como um ambiente de lazer, encontros, festas e sociabilidades diversas. Na segunda metade do século XX, observou-se o início do avanço das águas do mar em direção à área construída de Atafona. O mar avançou e começou a “engolir” as casas, as ruas e as quadras do local. A paisagem transformou-se paulatinamente em uma exposição de ruínas. Este ensaio apresenta imagens das ruínas de Atafona, captadas em momentos distintos do século XXI, para contar um pouco da história do lugar e das transformações da paisagem.
Memória reparadora: endereçando amnésia, performando trauma
Authors: Taylor Diana
Published: June 2023

Desde o início da Covid-19, muitos de nós tivemos que lidar com o trauma da perda – a perda de vidas, o desaparecimento de meios de vida, a destruição ambiental, os pressupostos sobre responsabilidade social e política. Sem opor experiências e tratamentos de trauma individualizados e coletivos, proponho que práticas performativas de memória reparativa e performances motivadas por experiências de trauma oferecem às vítimas, aos sobreviventes e ativistas formas para responder às repercussões globais e locais da pandemia, nos estimulando a imaginar futuros de vida possíveis.
Temporal Trends and Determinants of Stroke Risk in Patients With Medically Treated Asymptomatic Carotid Stenosis
Authors: Poorthuis Michiel H.F. , Solomon Yoel , Herings Reinier A.R. , Visseren Frank L.J. , Kappelle L. Jaap , Bots Michiel L. , Rissanen Ina , de Borst Gert J.
Published: June 2023

BACKGROUND:

Effectiveness of carotid procedures (surgery and stenting) in patients with asymptomatic carotid artery stenosis (ACAS) depends on the absolute risk reduction that patients might receive from these procedures. We aimed to quantify the risk of ipsilateral ischemic stroke and examined temporal trends and determinants of these risks in patients with ACAS treated conservatively.

METHODS:

We conducted a systematic review from inception to March 9, 2023, of peer-reviewed trials and cohort studies describing ipsilateral ischemic stroke risk in medically treated patients with ACAS of ≥50%. Risk of bias was assessed with an adapted version of the Quality in Prognosis Studies tool. We calculated the annual incidence rates of ipsilateral ischemic stroke. We explored temporal trends and associations of sex and degree of stenosis with ipsilateral ischemic stroke using Poisson metaregression analysis and incidence rate ratios, respectively.

RESULTS:

After screening 5915 reports, 73 studies describing ipsilateral ischemic stroke rates of 28 625 patients with midyear of recruitment ranging from 1976 to 2014 were included. The incidence of ipsilateral ischemic stroke was 0.98 (95% CI, 0.93–1.04) per 100 patient-years (median duration of follow-up, 3.3 years). The incidence decreased 24% with every 5 years more recent midyear of recruitment (rate ratio, 0.76 [95% CI, 0.73–0.78]). Incidence rates of ipsilateral ischemic stroke were lower in female patients (rate ratio, 0.74 [95% CI, 0.63–0.87]) and in patients with moderate versus severe stenosis when assessed in cohort studies, with incidence rate ratios of 0.41 ([95% CI, 0.35–0.49] cutoff, 70%) and 0.42 ([95% CI, 0.30–0.59] cutoff, 80%).

CONCLUSIONS:

Reported risks of ipsilateral ischemic stroke in patients with ACAS have declined 24% every 5 years from mid-1970s onward, further challenging the routine use of carotid procedures. Risks were lower in female patients and more than twice as high with severe compared with moderate ACAS. Inclusion of these findings in individualized risk assessment can help to determine the benefit of carotid procedures in selected individual patients with ACAS.

REGISTRATION:

URL:
https://www.crd.york.ac.uk/PROSPERO/
; Unique identifier: CRD42021222940.
Role of Sports Based on Big Data Analysis in Promoting the Physique and Health of Children and Adolescents
Authors: Wen Pengfei , Wang Menghua , Wu Jinsong
Published: June 2023

Healthy body is the foundation of young people's growth. With the popularization and globalization of the Internet, multimedia technology is rapidly changing the impact of traditional media on the growth of young people. The current health situation of young people is not optimistic. The decline in physical fitness, obesity and psychological dysplasia of adolescents have aroused the concern of all sectors of society. In recent years, the emergence and dissemination of big data (BD) has brought a new dimension to the value of data applications. The combination of BD and youth health services provides young people with good health opportunities. Through the recording, analysis and release of adolescent physical health data, the system has established an extensive knowledge database on adolescent physical and mental health, thus improving the physical health of adolescents. This paper summarized and combed the overview and application of BD, and analyzed and discussed the reasons for the continuous decline of young people's physique. Through the analysis of the application of BD in the promotion of young people's physical health, this paper proposed more achievable improvement strategies and plans, and then summarizes and discusses the experiment. According to the survey and experiment, the random simulation algorithm was introduced into daily exercise, diet and life preference. The new system and health improvement strategy designed for teenagers’ physical health using BD could help students improve their physical health by 55%.